Themis Medicare Announces Key Management Appointments, Releases Financial Results for June Quarter 2026
Themis Medicare Ltd has finalized major personnel changes and released its un-audited financial results for the quarter ending June 30, 2026. The company approved key management updates, including the appointment of a new Company Secretary and Compliance Officer, alongside the release of both standalone and consolidated financial statements.Governance and Key Personnel Changes
The Board of Directors of Themis Medicare held a meeting on August 13, 2026, to approve several corporate transactions. A primary action involved approving the resignation of Mr. Nagraj Mogaveera from the role of Interim Company Secretary and Compliance Officer, effective August 13, 2026. Mr. Mogaveera is transitioning into a new role within the company as Deputy Manager - Secretarial Department.Concurrently, the Board approved the appointment of Mr. Suresh Savaliya as Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP), also effective August 13, 2026.
Mr. Savaliya is a qualified Company Secretary and a Member of the Institute of Company Secretaries of India (ICSI). He brings 23 years of experience in Secretarial functions, Corporate Governance, and Compliances for listed companies. His previous experiences include roles with Reliance Industries Limited and Essel Group.
Financial Performance Review
The company disclosed its un-audited financial results for the quarter ended June 30, 2026, which were reviewed by the Audit Committee and prepared in accordance with Indian Accounting Standards (Ind AS).Standalone Results (Quarter Ended June 30, 2026)
Total Income stood at INR 8,795.06 Lakhs for the quarter, compared to INR 8,019.75 Lakhs during Q1 of the previous fiscal year and INR 9,757.77 Lakhs in FY ended December 31, 2025.
The company reported a profit of INR 2,873.72 Lakhs for the period after tax (excluding exceptional items), with Total Comprehensive Income at INR 2,855.34 Lakhs.
| Period | Revenue from Operations (Net) | Total Income | Expenses | Profit/(Loss) Before Tax |
|---|---|---|---|---|
| Q ended June 30, 2026 | 8,695.69 | 8,795.06 | 14,489.52 | 4,272.33 |
| Q ended March 31, 2026 | 7,653.05 | 8,019.75 | 7,806.17 | 213.58 |
| FY ended Dec 31, 2025 | 9,757.77 | 9,875.36 | 36,283.89 | (1,124.18) |
Consolidated Results (Quarter Ended June 30, 2026)
Total Income for the consolidated group was INR 8,825.06 Lakhs for the quarter, compared to INR 35,159.71 Lakhs in FY ended December 31, 2025, and INR 8,019.75 Lakhs in Q1 of the previous fiscal year.
The company recorded a Profit/Loss before tax of (INR 1,421.97) Lakhs for the quarter. Total comprehensive income for the period was INR 45.62 Lakhs.
| Period | Revenue from Operations (Net) | Total Income | Expenses | Profit/(Loss) Before Tax |
|---|---|---|---|---|
| Q ended June 30, 2026 | 8,695.69 | 8,795.06 | 14,489.69 | (5,694.63) |
| Q ended March 31, 2026 | 7,653.05 | 8,019.75 | 11,267.82 | (1,392.88) |
| FY ended Dec 31, 2025 | 34,223.55 | 35,159.71 | 36,283.89 | (1,125.49) |
Operational Highlights and Subsidiary Matters
The company reported a significant profit on the sale of shares amounting to Rs. 99.67 cr in the standalone results, achieved during the quarter ended June 30, 2026, from its investment in Gujarat Themis Biosyn Limited (an Associate Company).Regarding subsidiary matters, the company disclosed that it provided for Investments amounting to Rs. 0.76 lacs and Receivable and advances amounting to Rs. 128.63 Lacs concerning M/s Carpo Medicals Limited (UK), a wholly-owned subsidiary. This action followed the subsidiary being struck off by the Company House, UK, effective April 14, 2025.
The results also reflected an incremental impact of Rs. 86.53 lacs in Exceptional Items due to the notification of four Labour Codes by the Government of India.
THEMISMED Stock Price Movement
Themis Medicare Limited shares closed today after settling at ₹107.99, having shed 0.60% from previous close levels. During the post-market trading session, the equity recorded a volume of 275,970 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.